

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60550	SERIAL NO. 10/576,403
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Re et al.	
		FILING DATE November 10, 2006	GROUP 4131

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		Clinical Trial Study No. AVA100193. "A 24 week double-blind, randomized, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease."
		Clinical Trial Study No. AVA100468. "An open label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease."
		Diabetes Reduction Assessment with ramipril and rosiglitazone Medication Trial Investigators. <i>Lancet</i> , 368: 1096-1105 (2006).
		Diabetes Reduction Assessment with ramipril and rosiglitazone Medication Trial Investigators. Errata. <i>Lancet</i> , 368: 1770 (2006).
		Physician's Desk Reference: PDR – Avandia Tablets (GlaxoSmithKline).
		Risner et al. <i>The Pharmacogenomics Journal</i> , 6: 246-254 (2006).
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.